Douglas Ingram
2017
In 2017, Douglas Ingram earned a total compensation of $56.9M as President and Chief Executive Officer at Sarepta Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $420,875 |
|---|---|
| Option Awards | $44,484,000 |
| Salary | $337,500 |
| Stock Awards | $11,607,750 |
| Other | $16,116 |
| Total | $56,866,241 |
Ingram received $44.5M in option awards, accounting for 78% of the total pay in 2017.
Ingram also received $420.9K in non-equity incentive plan, $337.5K in salary, $11.6M in stock awards and $16.1K in other compensation.
Rankings
In 2017, Douglas Ingram's compensation ranked 20th out of 14,666 executives tracked by ExecPay. In other words, Ingram earned more than 99.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 20 out of 14,666 | 100th |
Division Manufacturing | 5 out of 5,770 | 100th |
Major group Chemicals And Allied Products | 1 out of 2,074 | 100th |
Industry group Drugs | 1 out of 1,730 | 100th |
Industry Pharmaceutical Preparations | 1 out of 1,329 | 100th |
Source: SEC filing on April 26, 2018.
Ingram's colleagues
We found six more compensation records of executives who worked with Douglas Ingram at Sarepta Therapeutics in 2017.
2017
Edward Kaye
Sarepta Therapeutics
Chief Executive Officer
2017
Guriqbal Basi
Sarepta Therapeutics
Chief Scientific Officer
2017
Alexander Cumbo
Sarepta Therapeutics
Senior Vice President, Chief Commercial Officer
2017
Sandesh Mahatme
Sarepta Therapeutics
Chief Financial Officer
2017
David Howton
Sarepta Therapeutics
General Counsel
2017
Catherine Stehman-Breen
Sarepta Therapeutics
Chief Medical Officer
News
Sarepta Therapeutics CSO Louise Rodino-Klapac's 2021 pay rises 17% to $8.5M
April 25, 2022
Sarepta Therapeutics CSO Louise Rodino-Klapac receives $7.3M in 2020
April 20, 2021
Sarepta Therapeutics CSO Gilmore MMSc's 2019 pay slips 20% to $5.2M
April 21, 2020
Sarepta Therapeutics CSO Gilmore MMSc receives $6.4M in 2018
April 26, 2019